Do you want to read an article? Please log in or register.
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
Type 1 DiabetesGlycemic Control
COMMENTED
Related content
COMMENTED
Type 1 Diabetes
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.1111/dom.14060.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Diabetes Care.
Jabbour SA, Frìas JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C
doi: 10.2337/dc18-0680.
Type 2 DiabetesGlycemic Control
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
Diabetes Obes Metab.
Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J
doi: 10.1111/dom.13594.
Type 1 Diabetes
Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2
Diabetes Care.
Mathieu C, Dandona P, Phillip M, Oron T, Lind M, Hansen L, Thorén F, Xu J, Langkilde AM; DEPICT-1 and DEPICT-2 Investigators
doi: 10.2337/dc18-1983.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study
Diabetes Obes Metab.
Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A
doi: 10.1111/dom.13473.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Lancet Diabetes Endocrinol.
Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA
doi: 10.1016/
Glycemic Control
Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial
Diabetes Care.
Cardoso CRL, Leite NC, Carlos FO, Loureiro AA, Viegas BB, Salles GF
doi: 10.2337/dc17-0374.
COMMENTED
Type 2 Diabetes
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Lancet.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A
doi: 10.1016/S0140-6736(18)32260-8.
Type 2 Diabetes
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study
Diabetes Obes Metab.
Del Prato S, Kang J, Trautmann ME, Stewart J, Sorli CH, Derwahl M, Soto A, Yoon KH
doi: 10.1111/dom.14020.